Isatchenkia orientalis CRISPR / Cas9 gene editing system and application thereof
By constructing a dedicated CRISPR/Cas9 gene editing system in Oriental Issa yeast, the problem that the CRISPR/Cas9 system cannot be replicated and expressed in this strain was solved, efficient gene editing was achieved, simplified editing steps and improved editing efficiency .
Patent Information
- Application Number
- CN202410966966.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-08
AI Technical Summary
Oriental Issa yeast has cumbersome steps in the gene editing process, and the existing CRISPR/Cas9 system cannot replicate and express stably in this strain, resulting in low editing efficiency.
A CRISPR/Cas9 gene editing system dedicated to Oriental Issa yeast was constructed. By replacing the gRNA promoter in the pRCC-N plasmid with the IOTEF1 gene promoter and replacing the Cas9 sequence with the IOCas9 sequence, the Cas9-gRNA fusion plasmid pIO was constructed. -CAS1.0, ensures efficient transcription and expression of plasmids in Oriental Issa yeast.
It achieves efficient and stable gene editing in Oriental Issa yeast, significantly improves the gene editing rate and editing efficiency, and simplifies the editing steps.
Smart Images

Figure CN118910116A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of genome editing technology, and in particular to an I. orientalis CRISPR / Cas9 gene editing system and its application. Background Art
[0002] Microbial genome modification mainly relies on two biological mechanisms: endogenous homologous recombination repair (HDR) and non-homologous end joining (NHEJ). The basic process of HDR is that after double-strand breaks (DSBs) occur in the genome, the donor DNA (sequence is homologous to the sequences on both sides of the break site) undergoes homologous recombination with the damaged genome sequence at the break site to achieve repair. This process is not easy to introduce insertion or deletion mutations. The basic process of NHEJ is that the two ends of the broken DNA are directly connected without the help of donor DNA-mediated homologous recombination. This process is prone to insertion or deletion mutations and causes codon displacement. Under normal conditions, the probability of HDR causing homologous recombination is very low, but the efficiency of recombination can be greatly increased by creating cuts on the genome through endonucleases and converting linear homologous DNA fragments into cells. Moreover, combining endonucleases with elements with site recognition functions can achieve efficient and specific genome modification.
[0003] CRISPR / Cas (Clustered Regulatory Interspaced Short PalindromicRepeats / CRISPR associated) is a biological defense system widely found in bacteria and archaea. Among them, the modified type II system, CRISPR / Cas9, has become a widely used genome modification tool. Under the mediation of guide RNA (gRNA), the Cas9 protein recognizes the protospacer adjacent motif (PAM) and its upstream 20bp sequence on the genome, and produces a double-stranded cut at the 3bp position upstream of PAM. When donor DNA is provided at the same time, the gene double-stranded cut by CRISPR / Cas9 can be recombined into a new sequence in the form of HDR to achieve the purpose of genetic modification. In Saccharomyces cerevisiae, there are many examples of genome modification using the CRISPR / Cas9 system, including gene point mutation, gene knockout and gene insertion. For example, the pRCC-N plasmid popular in the prior art has both the Cas9 gene sequence and the gRNA element, which can achieve efficient genome modification in Saccharomyces cerevisiae through a single transformation.
[0004] Issatchenkia orientalis is a highly tolerant yeast to harsh environmental conditions and is a promising metabolic engineering host that can produce fuels and chemicals from cellulose hydrolysates containing fermentation inhibitors under acidic conditions. Currently, editing of Issatchenkia orientalis requires first constructing a URA3 auxotrophic mutation and then editing other genes, which is a cumbersome process. Therefore, it is necessary to construct an efficient and safe CRISPR / Cas9 system that can stably replicate and express in Issatchenkia orientalis and reduce the number of editing steps for the development of biotechnology. Summary of the invention
[0005] The purpose of the present application is to overcome the deficiencies of the above-mentioned prior art and to provide an I. orientalis CRISPR / Cas9 gene editing system and its application.
[0006] To achieve the above purpose, the technical solution adopted by this application is:
[0007] In a first aspect, the present application provides an I. orientalis CRISPR / Cas9 gene editing system, wherein the I. orientalis CRISPR / Cas9 gene editing system comprises a Cas9-gRNA fusion plasmid and a donor DNA sequence;
[0008] The Cas9-gRNA fusion plasmid includes a pRCC-N plasmid skeleton, an IOCas9 sequence, and a gRNA gene expression cassette sequence;
[0009] The gRNA gene expression cassette includes a gRNA promoter, a guide sequence, a scaffold RNA sequence and a terminator from upstream to downstream;
[0010] The gRNA promoter is the IOTEF1 gene promoter, and the nucleotide sequence is shown in SEQ ID NO: 1;
[0011] The nucleotide sequence of the IOCas9 sequence is shown in SEQ ID NO:2.
[0012] In the prior art, the pRCC-N plasmid used in yeast has both the Cas9 gene sequence and the gRNA element, which can achieve efficient genome modification in yeast through a single transformation, but cannot be stably replicated and expressed in I. orientalis.
[0013] The present application constructs a CRISPR / Cas9 gene editing system that is specific to I. orientalis and can stably replicate, express, and perform genetic modification in I. orientalis.
[0014] Among them, the use of the IOCas9 sequence of the present application can improve the editing efficiency and realize rapid editing of I. orientalis. The present application replaces the gRNA promoter in the pRCC-N plasmid with the IOTEF1 gene promoter, which can enhance the expression of gRNA, achieve the purpose of improving the editing efficiency, and ensure that the gRNA in the plasmid is efficiently transcribed in I. orientalis.
[0015] As a preferred embodiment of the I. orientalis CRISPR / Cas9 gene editing system described in the present application, the nucleotide sequence of the guide sequence is shown in SEQ ID NO:3; the nucleotide sequence of the scaffold RNA sequence is shown in SEQ ID NO:4.
[0016] As a preferred embodiment of the I. orientalis CRISPR / Cas9 gene editing system described in the present application, the Cas9-gRNA fusion plasmid comprises a nucleotide sequence that is at least 80% identical to the sequence SEQ ID NO:5.
[0017] Preferably, the Cas9-gRNA fusion plasmid comprises a nucleotide sequence that is at least 80%, 82%, 85%, 88%, 90%, 92%, 95%, 98%, 99%, 99.5%, 99.9% or 100% identical to the sequence of SEQ ID NO:5.
[0018] More preferably, the Cas9-gRNA fusion plasmid comprises a nucleotide sequence that is at least 99% identical to the sequence of SEQ ID NO:5.
[0019] The Cas9-gRNA fusion plasmid of the present application has a high copy number in I. orientalis yeast cells, can be stably replicated and expressed, and can quickly edit I. orientalis yeast with a high gene editing rate.
[0020] As a preferred embodiment of the I. orientalis CRISPR / Cas9 gene editing system described in the present application, the donor DNA sequence is a sequence homologous to the sequences on both sides of the target site, the donor DNA sequence is a linear double-stranded DNA, and the nucleotide sequence of the linear double-stranded DNA is shown in SEQ ID NO:6.
[0021] A preferred embodiment of the I. orientalis CRISPR / Cas9 gene editing system described in the present application, and a method for constructing the Cas9-gRNA fusion plasmid, comprises the following steps:
[0022] 1) The gRNA promoter in the pRCC-N plasmid was replaced with the IOTEF1 gene promoter to construct the plasmid pRCC-N-pTEF1;
[0023] 2) The Cas9 sequence in the pRCC-N-pTEF1 plasmid was replaced with IOCas9 suitable for expression in I. orientalis to construct the plasmid pIOCas9-pTEF1;
[0024] 3) The promoter of the resistance screening marker gene in the pIOCas9-pTEF1 plasmid was truncated to 200 bp to obtain a Cas9-gRNA fusion plasmid named pIO-CAS1.0.
[0025] As a preferred embodiment of the I. orientalis CRISPR / Cas9 gene editing system described in the present application, the resistance screening marker gene includes the screening marker gene NrsR.
[0026] The present application provides the application of the above-mentioned I. orientalis CRISPR / Cas9 gene editing system in editing the I. orientalis genome.
[0027] Preferably, the application is: replacing the guide sequence of the Cas9-gRNA fusion plasmid with a guide sequence targeting the ADE2 gene to construct a pIO-CAS9-ADE2 plasmid (for knocking out the ADE2 gene);
[0028] Using the I. orientalis genome as a template, DNA fragments of 500-1000 bp on both sides of the ADE2 gene were amplified, and the two purified DNA fragments were subjected to fusion PCR to obtain the donor DNA sequence, which was named ADE2-donor;
[0029] The pIO-CAS9-ADE2 plasmid and the donor DNA sequence were transformed into the I. orientalis yeast cells to obtain the edited I. orientalis yeast cells.
[0030] By comparing the editing efficiency of the pIO-CAS9-ADE2 plasmid constructed in the present application and the pRCC-N plasmid in I. orientalis, it can be seen that the editing efficiency of the pIO-CAS9-ADE2 plasmid constructed in the present application in I. orientalis is significantly higher than that of the pRCC-N plasmid.
[0031] Moreover, the copy number of pIO-CAS9-ADE2 plasmid in I. orientalis was significantly higher than that of pRCC-N plasmid in I. orientalis.
[0032] Preferably, the transformation adopts LiAc / SS carrier DNA / PEG method.
[0033] Compared with the prior art, this application has the following beneficial effects:
[0034] The present application constructs a CRISPR / Cas9 gene editing system that is dedicated to I. orientalis and can be stably replicated, expressed, and genetically modified in I. orientalis. Among them, the Cas9-gRNA fusion plasmid constructed in the present application has a high copy number in I. orientalis cells, can be stably replicated and expressed, and can quickly edit I. orientalis with a high gene editing rate. The present application also utilizes the promoter sequence of the modified resistance screening marker gene to increase the copy number of the knockout plasmid in yeast, and can directly edit the I. orientalis strain. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1 This is a comparison chart of the editing efficiency of the Cas9-gRNA fusion plasmid (pIO-CAS1.0) and pRCC-N plasmid in I. orientalis yeast of this application;
[0036] Figure 2 This is a comparison chart of the copy numbers of the Cas9-gRNA fusion plasmid (pIO-CAS1.0) and the pRCC-N plasmid in I. orientalis;
[0037] Figure 3 is the plasmid map of pRCC-N plasmid;
[0038] Figure 4This is the plasmid map of the Cas9-gRNA fusion plasmid (pIO-CAS1.0) of this application. DETAILED DESCRIPTION
[0039] In order to better illustrate the purpose, technical solutions and advantages of the present application, the present application will be further described below in conjunction with the accompanying drawings and specific embodiments.
[0040] In the following examples, the experimental methods used are conventional methods unless otherwise specified, and the materials, reagents, etc. used are all commercially available unless otherwise specified.
[0041] The present application constructs a safe and efficient CRISPR / Cas9 gene editing system specifically for I. orientalis, which can stably replicate, express, and perform genetic modification in I. orientalis, and the gene editing system is named pIO-CAS1.0.
[0042] In the following examples, the I. orientalis CRISPR / Cas9 gene editing system includes a Cas9-gRNA fusion plasmid and a donor DNA sequence;
[0043] The Cas9-gRNA fusion plasmid includes a pRCC-N plasmid skeleton, an IOCas9 sequence, and a gRNA gene expression cassette sequence;
[0044] The gRNA gene expression cassette includes a gRNA promoter, a guide sequence, a scaffoldRNA sequence and a terminator from upstream to downstream;
[0045] The gRNA promoter is the IOTEF1 gene promoter, and the nucleotide sequence is shown in SEQ ID NO: 1;
[0046] The nucleotide sequence of the IOCas9 sequence is shown in SEQ ID NO:2.
[0047] The nucleotide sequence of the guide sequence is shown in SEQ ID NO:3; the nucleotide sequence of the scaffold RNA sequence is shown in SEQ ID NO:4.
[0048] The nucleotide sequence of the Cas9-gRNA fusion plasmid is shown in SEQ ID NO:5.
[0049] The donor DNA sequence is a linear double-stranded DNA, and the nucleotide sequence of the linear double-stranded DNA is shown in SEQ ID NO:6.
[0050] The sequences involved are shown in the following table:
[0051]
[0052]
[0053]
[0054]
[0055]
[0056] Example 1. Construction of Cas9-gRNA fusion plasmid (pIO-CAS1.0 plasmid)
[0057] The construction method of the pIO-CAS1.0 plasmid of this embodiment comprises the following steps:
[0058] 1) The gRNA promoter in the pRCC-N plasmid was replaced with the promoter of the TEF1 gene in Saccharomyces cerevisiae (IOTEF1 gene promoter, the nucleotide sequence is shown in SEQ ID NO: 1).
[0059] Using Saccharomyces cerevisiae as template, primers TEF1-F and TEF1-R were used to amplify the TEF1 promoter sequence. Using pRCC-N plasmid as template, primers pTEF1-F and pTEF1-R were used to amplify the TEF1 promoter sequence.
[0060] The pRCC-N amplified and purified product was digested with endonuclease DpnⅠ, and then the whole system was incubated at 80℃ for 20min. The incubated product and the TEF1 amplified and purified product were mixed according to the instructions of the one-step cloning kit (Vazyme) and incubated at 50℃ for 15min for homologous recombination connection. 10μL of the recombinant product was added to 100μL DH5α competent cells, placed on ice for 30min, heat-shocked at 42℃ for 45s, and then added to 1mL LB liquid medium for shaking culture at 37℃ for 1h, and then spread on LB solid medium with Amp resistance (final working concentration: 100mg / L), and inverted at 37℃ until a single clone grew out. Five single clones were picked and shaken in LB liquid medium. After positive PCR detection and sequencing confirmation, the plasmid was extracted and stored, and named pRCC-N-pTEF1.
[0061] 2) The Cas9 nucleotide sequence on the pRCC-N-pTEF1 plasmid was replaced with IOCas9 optimized for I. orientalis.
[0062] The nucleotide sequence of the IOCas9 sequence is shown in SEQ ID NO: 2. The IOCas9 sequence was synthesized by Beijing Qingke (Beijing, China) and amplified with primers IOCas9-F and IOCas9-R. The pRCC-N-pTEF1 plasmid was used as a template and amplified with primers pCAS-F1 and pCAS-R1.
[0063] The purified products of pRCC-N-pTEF1 and IOCas9 were digested with endonuclease DpnⅠ, and then the whole system was incubated at 80℃ for 20min. The incubated products were mixed according to the instructions of the one-step cloning kit and incubated at 50℃ for 15min for homologous recombination. 10μL of the recombinant product was added to 100μL DH5α competent cells, placed on ice for 30min, heat-shocked at 42℃ for 45s, and then added to 1mL LB liquid medium for shaking culture at 37℃ for 1h, spread on Amp (final working concentration: 100mg / L) resistant LB solid medium, and inverted at 37℃ until a single clone grew out. Five single clones were selected for shaking culture in LB liquid medium. After positive PCR detection and sequencing confirmation, the plasmid was extracted and stored, named pIOCas9-pTEF1.
[0064] 3) The promoter of the resistance selection marker gene in the plasmid pIOCas9-pTEF1 was truncated to 200 bp.
[0065] The pIOCas9-pTEF1 plasmid was used as a template and pIOCas9-deP-F and pIOCas9-deP-R were used for amplification.
[0066] The amplified and purified product of pIOCas9-pTEF1 was digested with endonuclease DpnⅠ, and then the whole system was incubated at 80℃ for 20min. 10μL of the product treated with Dpn I was added to 100μL DH5α competent cells, placed on ice for 30min, heat-shocked at 42℃ for 45s, and then added to 1mL LB liquid medium for shaking culture at 37℃ for 1h, and then spread on Amp (final working concentration: 100mg / L) resistant LB solid medium, and inverted cultured at 37℃ until a single clone grew out. Five single clones were selected for shaking culture in LB liquid medium. After positive PCR detection and sequencing confirmation, the final transformation completed plasmid was obtained, that is, the Cas9-gRNA fusion plasmid, named pIO-CAS1.0 (nucleotide sequence as shown in SEQ ID NO.5).
[0067] The amplification system was: 25 μl of 2×Phanta Max Buffer (Vazyme), 1 μl of dNTP (10 mM of each dNTP), 20 ng of DNA template, 2 μl of each primer (10 μM), 1 μl of Phanta Max Super-Fidelity DNA polymerase (2.5 U / μl), and 20 μl of distilled water, with a total volume of 50 μl.
[0068] Amplification conditions were as follows: pre-denaturation at 95°C for 3 minutes (1 cycle); denaturation at 95°C for 15 seconds, annealing at 56°C for 15 seconds, and extension at 72°C for 1 minute (30 cycles); and extension at 72°C for 5 minutes (1 cycle).
[0069] Digestion system: 10× digestion buffer (TAKARA) 5 μL, Dpn I 1 μL, purified DNA product 20 μL, distilled water 24 μL, total volume 50 μL.
[0070] Digestion conditions: 37°C warm bath for 3 hours.
[0071] One-step cloning system: 2×ClonExpress Mix (Vazyme) 5 μL, linearized vector 1.5 μL, total insert fragment 3.5 μL, total volume 10 μL.
[0072] The primer sequences used in the above-mentioned pIO-CAS1.0 plasmid are shown in Table 1.
[0073] Table 1 Primer sequences used for plasmid construction
[0074]
[0075] Example 2: Knockout of the ADE2 gene of the I. orientalis strain
[0076] 1. Construction of pIO-CAS9-ADE2 and pRCC-N-ADE2 plasmids and donor DNA fragment (ADE2-donor)
[0077] 1) The guide sequences of the Cas9-gRNA fusion plasmid and the original pRCC-N plasmid were replaced with the guide sequences targeting the ADE2 gene to construct pIO-CAS9-ADE2 and pRCC-N-ADE2 plasmids, specifically:
[0078] Using pIO-CAS1.0 and pRCC-N as templates, PCR amplification was performed using primers ADE2-SG-F: GAGACAGCATTGCAAAATGTGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGG and ADE2-SG-R: ACATTTTGCAATGCTGTCTCTTTGCAGTACTATATAAAGTTGATAATAAGGG, and agarose gel electrophoresis was performed to obtain two single target bands, pIO-CAS9-ADE2 and pRCC-N-ADE2 plasmids; using Issatchengensis orientalis as template Template, PCR amplification was performed using two primer pairs ADE2-LF: GGTAAATCCATTCTTTTATTCTTGGGG and ADE2-LR: TATTTGCGTTTATAAGTCCTTGTTGCTATACTAGATC and ADE2-RF: ATAAAATATCTATAACGATTCGACTAATAATTTAG and ADE2-RR: ATCTTCAGTTGGTTGTTTAACTATGGAATATG, and verified by agarose gel electrophoresis, obtaining two single target bands ADE2-L, ADE2-R;
[0079] 2) After the above single bands pIO-CAS9-ADE2 and pRCC-N-ADE2 were purified and recovered, they were digested with endonuclease DpnⅠ, and then the whole system was incubated at 80°C for 20 minutes. 10 μL of the product was added to 100 μL DH5α competent cells, placed on ice for 30 minutes, heat-shocked at 42°C for 45 seconds, and then added to 1 mL LB liquid culture medium for shaking culture at 37°C for 1 hour, and then spread on Amp (final working concentration: 100 mg / L) resistant LB solid culture medium, and inverted cultured at 37°C until a single clone grew out. Five single clones were selected and shaken in LB liquid culture medium. After positive PCR detection and sequencing confirmation, two ADE2 gene knockout plasmids were obtained.
[0080] 3) After the single target bands ADE2-L and ADE2-R are purified and recovered, the mixture of ADE2-L and ADE2-R is used as a common template, and PCR fusion is performed with primers ADE2-LF and ADE2-RR. The fusion product is purified and sent for sequencing verification to obtain the donor DNA sequence, namely ADE2-donor.
[0081] 2. Conversion
[0082] The constructed plasmids pIO-CAS9-ADE2, pRCC-N-ADE2 and ADE2-donor were mixed and transformed into I. orientalis using the LiAc transformation method. The resulting transformation bacterial solution was spread on YPD-NrsR plates and cultured inverted in a 30°C incubator for 2-4 days. The positive transformants were verified by colony PCR. The verification primers were ADE2-JD-F: ACAAGCACAGATTTCGTGAATAATC and ADE2-JD-R: ATCTTCAGTTGGTTGTTTAACTATGG. The bacteria were maintained to obtain the I. orientalis ADE2 knockout bacteria.
[0083] Comparison of the effects of pIO-CAS9-ADE2 plasmid and pRCC-N-ADE2 plasmid in editing I. orientalis:
[0084] Comparison of the editing efficiency of the Cas9-gRNA fusion plasmid (pIO-CAS1.0) and pRCC-N plasmid in I. orientalis yeast Figure 1 As shown. The copy number comparison of the Cas9-gRNA fusion plasmid (pIO-CAS1.0) and the pRCC-N plasmid in the oriental yeast is shown. Figure 2 The plasmid maps of the pRCC-N plasmid and the Cas9-gRNA fusion plasmid (pIO-CAS1.0) of the present application are shown in Figure 3-4 shown.
[0085] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present application rather than to limit the scope of protection of the present application. Although the present application has been described in detail with reference to the preferred embodiments, ordinary technicians in this field should understand that the technical solution of the present application can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present application.
Claims
1. A CRISPR / Cas9 gene editing system of Issatchenia orientalis, characterized in that: The I. orientalis CRISPR / Cas9 gene editing system includes a Cas9-gRNA fusion plasmid and a donor DNA sequence; The Cas9-gRNA fusion plasmid includes a pRCC-N plasmid skeleton, an IOCas9 sequence, and a gRNA gene expression cassette sequence; The gRNA gene expression cassette includes a gRNA promoter, a guide sequence, a scaffold RNA sequence and a terminator from upstream to downstream; The gRNA promoter is the IOTEF1 gene promoter, and the nucleotide sequence is shown in SEQ ID NO: 1; The nucleotide sequence of the IOCas9 sequence is shown in SEQ ID NO:
2.
2. The I. orientalis CRISPR / Cas9 gene editing system according to claim 1, characterized in that The nucleotide sequence of the guide sequence is shown in SEQ ID NO:3; the nucleotide sequence of the scaffold RNA sequence is shown in SEQ ID NO:
4.
3. The I. orientalis CRISPR / Cas9 gene editing system according to claim 1, characterized in that The Cas9-gRNA fusion plasmid comprises a nucleotide sequence that is at least 80% identical to sequence SEQ ID NO:
5.
4. The I. orientalis CRISPR / Cas9 gene editing system according to claim 3, characterized in that The Cas9-gRNA fusion plasmid comprises a nucleotide sequence that is at least 99% identical to sequence SEQ ID NO:
5.
5. The I. orientalis CRISPR / Cas9 gene editing system according to claim 1, characterized in that The donor DNA sequence is a linear double-stranded DNA, and the nucleotide sequence of the linear double-stranded DNA is shown in SEQ ID NO:
6.
6. The I. orientalis CRISPR Cas9 gene editing system according to any one of claims 1 to 4, characterized in that The method for constructing the Cas9-gRNA fusion plasmid comprises the following steps: 1) The gRNA promoter in the pRCC-N plasmid was replaced with the IOTEF1 gene promoter to construct the plasmid pRCC-N-pTEF1; 2) The Cas9 sequence in the pRCC-N-pTEF1 plasmid was replaced with IOCas9 suitable for expression in I. orientalis to construct the plasmid pIOCas9-pTEF1; 3) The promoter of the resistance screening marker gene in the pIOCas9-pTEF1 plasmid was truncated to 200 bp to obtain a Cas9-gRNA fusion plasmid named pIO-CAS1.
0.
7. The I. orientalis CRISPR Cas9 gene editing system according to claim 6, characterized in that The resistance selection marker gene includes the selection marker gene NrsR.
8. Use of the CRISPR / Cas9 gene editing system of I. orientalis as described in any one of claims 1 to 7 in editing the genome of I. orientalis.
9. The use according to claim 8, characterized in that The guide sequence of the Cas9-gRNA fusion plasmid was replaced with a guide sequence targeting the ADE2 gene to construct a pIO-CAS9-ADE2 plasmid; Using the I. orientalis genome as a template, 500-1000 bp DNA fragments on both sides of the ADE2 gene were amplified, and the two purified DNA fragments were subjected to fusion PCR to obtain the donor DNA sequence; The pIO-CAS9-ADE2 plasmid and the donor DNA sequence were transformed into the I. orientalis yeast cells to obtain the edited I. orientalis yeast cells.
10. The use according to claim 9, characterized in that The transformation used the LiAc / SS carrier DNA / PEG method.
Citation Information
Cited By
Engineering pichia kudriavzevii and application thereof
CN121801724A
